Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment (RESTORE-PC)

30 giugno 2026 aggiornato da: Duke University

RESTORE-PC: Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment: A Randomized Feasibility Trial

This study is being done at Duke Health and includes adult men who have been treated for localized prostate cancer. The goal is to see if it is feasible and acceptable to offer sex therapy by telehealth after prostate cancer treatment.

All participants receive pelvic floor physical therapy and education about penile rehabilitation, including use of a vacuum erection device. Participants are randomly assigned to one of two groups. One group receives pelvic floor physical therapy plus telehealth sex therapy, with about ten sessions over six months. The other group receives pelvic floor physical therapy alone.

Participants complete questionnaires about urinary and sexual health at the start of the study and over the next two years. Short interviews are also done at 6 and 12 months. Medicines for erectile function are prescribed as part of usual clinical care and are not part of the study treatment.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a two-arm, parallel-group, randomized feasibility trial conducted at Duke University Health System. Eligible adult men treated for localized prostate adenocarcinoma with erectile nerve-sparing radical prostatectomy, radiotherapy, or cryoablation at Duke Health who are initiating pelvic floor physical therapy (PFPT) will be randomized 1:1 to PFPT plus sex therapy or PFPT alone. PFPT is delivered as part of routine clinical survivorship care. All enrolled participants will receive penile rehabilitation education and a vacuum erection device (VED) as part of standard PFPT, in addition to clinician-prescribed PDEi if applicable.

The sex therapy intervention is delivered by telehealth as 10 sessions of approximately 45 minutes over 6 months. Baseline assessment occurs after completion of localized treatment and before initiation of study-linked rehabilitation.

Patient-reported outcome measures will be collected at baseline and at 3, 6, 9, 12, 18, and 24 months post-baseline for feasibility of longer follow-up. Semi-structured qualitative interviews will be offered at 6 and 12 months post-baseline.

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Stati Uniti
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Duke University Medical Center
        • Contatto:
        • Investigatore principale:
          • Rebecca A Shelby, PhD
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria

  • Age 18 years or older.
  • Biopsy-confirmed localized prostate adenocarcinoma.
  • Treated with nerve-sparing radical prostatectomy, radiotherapy, or cryoablation as primary index therapy for prostate cancer at Duke Health.
  • Initiating pelvic floor physical therapy as part of routine clinical care.
  • Pre-treatment International Index of Erectile Function-5 (IIEF-5) score meeting the eligibility threshold, with or without aids, determined by medical record chart review (when documented within 4 months prior to index treatment) or collected post-treatment with participant recall anchored to the month prior to treatment. Eligibility threshold for the IIEF-5 is at or above 17.
  • Able to read and understand English to complete patient-reported outcome measures.
  • Ability to provide informed consent.

Exclusion Criteria

  • Any androgen deprivation therapy (ADT) given for prostate cancer treatment or planned during the intervention or follow-up period, including neoadjuvant, concurrent, or adjuvant ADT.
  • Recieved non-nerve-sparing treatment (when applicable).
  • Unable to engage in pelvic floor physical therapy or penile rehabilitation protocol.
  • Need for additional or secondary prostate cancer treatment during the intervention period.
  • Documented cognitive impairment or impairment that would interfere with participation.
  • Major psychiatric concern that would interfere with ability to consent or participate, such as schizophrenia, based on the medical record or treating clinician assessment.
  • Inability to complete study video visits or questionnaires.
  • History of prior local or systemic treatment for prostate cancer

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: PFPT + Sex Therapy
Ten 45-minute telehealth sex therapy sessions over 6 months plus standard pelvic floor physical therapy and penile rehabilitation education (including provision of VED).
Comportamentale: Sex Therapy
Telehealth sex therapy integrating psychoeducation, acceptance and commitment therapy strategies, and sensate focus skills; 10 sessions (~45 minutes) over 6 months delivered by a psychologist.
Comportamentale: Pelvic Floor Physical Therapy
Routine clinical survivorship care including pelvic floor assessment, exercises, behavioral strategies for urinary incontinence, and ongoing therapist-guided rehabilitation.
Dispositivo: Vacuum Erection Device (VED)
FDA-cleared manual vacuum pump provided to all participants with education in safe use for penile rehabilitation; not evaluated as an investigational device.
Comparatore attivo: PFPT Alone (Standard Care)
Standard pelvic floor physical therapy and penile rehabilitation education (including provision of VED); no study-delivered sex therapy.
Comportamentale: Pelvic Floor Physical Therapy
Routine clinical survivorship care including pelvic floor assessment, exercises, behavioral strategies for urinary incontinence, and ongoing therapist-guided rehabilitation.
Dispositivo: Vacuum Erection Device (VED)
FDA-cleared manual vacuum pump provided to all participants with education in safe use for penile rehabilitation; not evaluated as an investigational device.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Recruitment feasibility as measured by number of participants recruited
Lasso di tempo: From initiation of recruitment to completion of accrual, up to 1 year
Accrual rate will be used to assess feasibility of recruiting participants to the study target of 30 participants. This feasibility trial is designed to estimate key process parameters with precision rather than to test efficacy hypotheses
From initiation of recruitment to completion of accrual, up to 1 year
Enrollment feasibility, as measured by consent rate
Lasso di tempo: From initiation of recruitment to completion of accrual, up to 1 year
Consent rate will be used to assess enrollment feasibility. This measure reflects the proportion of eligible participants who provide informed consent after screening and outreach.
From initiation of recruitment to completion of accrual, up to 1 year
Randomization feasibility
Lasso di tempo: From initiation of recruitment to completion of accrual, up to 1 year
Randomization rate will be used to assess the proportion of consented eligible participants who are randomized in a 1:1 ratio to pelvic floor physical therapy (PFPT) plus sex therapy or PFPT alone.
From initiation of recruitment to completion of accrual, up to 1 year
Retention feasibility
Lasso di tempo: 12 months
Retention will be used to assess the proportion of randomized participants who remain in the study through the 12-month follow-up timepoint.
12 months
Number of participants who complete study assessments
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
Assessment completion will be used to assess feasibility of longitudinal data collection across the planned study schedule. Scheduled patient-reported outcome assessments occur at baseline and during follow-up contacts.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
Number of participants who participate in pelvic floor physical therapy (PFPT)
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months
Intervention exposure metrics will be used to assess feasibility of delivering and receiving the rehabilitation pathway. This includes participation in PFPT.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months
Number of participants who participate in sex therapy
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months
Intervention exposure metrics will be used to assess feasibility of delivering and receiving the rehabilitation pathway. This includes sex therapy participation in the intervention arm.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months
Number of participants who use recommended penile rehabilitation
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months
Intervention exposure metrics will be used to assess feasibility of delivering and receiving the rehabilitation pathway. This includes recommended penile rehabilitation use patterns including vacuum erection device (VED) and PDE-5i use as measured via adherence logs.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months
Fidelity-monitoring feasibility
Lasso di tempo: During the 6-Month sex therapy intervention window
Fidelity-monitoring feasibility will be assessed using audio recording of sex therapy sessions and audit of a planned 20% sample of recordings using fidelity checklists.
During the 6-Month sex therapy intervention window

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Acceptability of sex therapy, as measured by the Satisfaction with Therapy and Therapist Scale-Revised
Lasso di tempo: 6 Months
Participants assigned to sex therapy will complete the 13-item Satisfaction with Therapy and Therapist Scale-Revised specific to the sex therapy they are currently attending or have completed. The first 12 items assess agreement with statements related to therapy and therapist satisfaction on a 5-point scale from "strongly disagree" (1) to "strongly agree" (5). The 13th item asks how much the treatment helped with the specific problem that led the participant to therapy, with response options ranging from "made things a lot better" to "made things a lot worse."
6 Months
Acceptability of pelvic floor physical therapy, as measured by the Satisfaction with Therapy and Therapist Scale-Revised
Lasso di tempo: 12 Months
Participants in both arms will complete the 13-item Satisfaction with Therapy and Therapist Scale-Revised specific to pelvic floor physical therapy. The first 12 items assess agreement with statements related to therapy and therapist satisfaction on a 5-point scale from "strongly disagree" (1) to "strongly agree" (5). The 13th item asks how much the treatment helped with the specific problem or concern that led the participant to therapy, with response options ranging from "made things a lot better" to "made things a lot worse."
12 Months
Urinary symptoms and bother, as measured by the International Prostate Symptom Score with bother index/quality of life (IPSS with BI/QOL)
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
The International Prostate Symptom Score with bother index/quality-of-life assessment is an 8-item measure that will be used to assess urinary symptoms and urinary-related bother. The first 7 questions assess symptom severity and scores may range from 1 to 35, where higher scores indicate higher symptom severity. The final question assesses urinary-related bother on a scale of 0 to 6, where a higher score indicates higher bother.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
Erectile dysfunction as measured by the International Index of Erectile Function-5 (IIEF-5)
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
The International Index of Erectile Function-5 will be used to assess erectile function. At screening, if a pretreatment IIEF-5 is not available in the medical record, a screening IIEF-5 will be collected post-treatment with recall anchored to the month prior to treatment. Sum scores range from 5 to 25, where higher scores indicate higher erectile dysfunction.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
Sexual function and satisfaction as measured by the PROMIS Sexual Function and Satisfaction Male Brief Profile
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
The PROMIS Sexual Function and Satisfaction Measure male brief profile is an 8-item measure used to capture sexual function, sexual satisfaction, and reasons for no sexual activity without requiring partner status. Scores range from 5 to 40, where higher scores indicate higher sexual function and satisfaction.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
General health status and utility as measured by the PROMIS-16 Profile v2.1 (PROPr)
Lasso di tempo: Baseline and 12 Months
PROMIS-16 Profile v2.1 (PROPr) is a 16-item measure used to assess general health status and utility. Scores range from 16 to 80, with higher scores indicating worse health status and utility.
Baseline and 12 Months
General health status and utility as measured by the PROMIS Global Health
Lasso di tempo: Baseline and 12 Months
PROMIS Global Health is a 10-item measure used to assess general health status and utility. The first 9 items are measured on a 5-point Likert scale, for sum scores of 9 to 45, where higher scores indicate better general health status. The 10th item asks respondents to rate their pain on average in the past 7 days on a 10-point scale, where 0 is no pain and 10 is the worst pain imaginable.
Baseline and 12 Months
Depressive sympoms as measured by the Patient Health Questionnaire-8 scale
Lasso di tempo: Baseline and 12 Months
The Patient Health Questionnaire-8 will be used to assess depressive symptoms and psychosocial context. The Patient Health Questionnaire-9 total score ranges from 0 to 27 (scores of 5-9 are classified as mild depression; 10-14 as moderate depression; 15-19 as moderately severe depression; ≥ 20 as severe depression).
Baseline and 12 Months
Anxiety symptoms as measured by the Generalized Anxiety Disorder-7 scale
Lasso di tempo: Baseline and 12 Months
The Generalized Anxiety Disorder-7 questionnaire will be used to assess anxiety symptoms and psychosocial context. The Generalized Anxiety Disorder-7 score ranges from 0 to 21, where a higher score indicates greater anxiety.
Baseline and 12 Months
Trauma-related symptoms as measured by Primary Care PTSD Screen
Lasso di tempo: Baseline and 12 Months
The Primary Care PTSD Screen for DSM-5 (PC PTSD-5) is a 5-item measure used to assess trauma-related symptoms and psychosocial context. Scores range from 0 to 5, where the score is a count of 'yes' responses to 5 yes or no questions about the impact of the trauma in the previous month.
Baseline and 12 Months
Physical activity, as measured by the International Physical Activity Questionnaire
Lasso di tempo: Baseline and 12 Months
The International Physical Activity Questionnaire (IPAQ) short form will be used to assess physical activity. The IPAQ is a seven-item questionnaire that assesses the amount of time participants have spent doing physical activity (e.g., moderate physical activities, vigorous physical activities, walking) in the last seven days.
Baseline and 12 Months
Continence as measured by Continence Diary - Pad Count
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
The Continence Diary - Pad Count will be used to assess pad use and continence patterns. Participants will record pad use for 7 typical days. Social continence is defined as 0 to 1 pad per day.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
Use of medications and sexual aids as measured by Medication and Sexual Aids Inventory and Use Log
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
The Medication and Sexual Aids Inventory and Use Log will be used to track use of medications and sexual aids. The log captures whether items were used since the last survey, frequency, typical duration, and notes such as side effects, discomfort, bruising, and adjunct use.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months, 18 Months, 24 Months
Adherence and Barriers to Adherence
Lasso di tempo: Baseline and 12 Months
Study-specific adherence and barrier items will be used to understand what makes the rehabilitation program easier or harder to follow. Items address PFPT adherence and barriers, sex therapy adherence and barriers if assigned, and VED use adherence and barriers.
Baseline and 12 Months
PDE5 inhibitor medication adherence, as measured by Screening Tool for AdheRence to medicineS (15-STARS ED)
Lasso di tempo: Baseline, 3 Months, 6 Months, 9 Months, 12 Months
The 15-STARS ED is a 15-item self-report questionnaire used to assess adherence to phosphodiesterase type 5 inhibitor medication when prescribed by the treating clinician. Sum scores range from 0 to 14 with higher scores indicating lower adherence.
Baseline, 3 Months, 6 Months, 9 Months, 12 Months
Sexual avoidance as measured by a Sexual Avoidance Questionnaire
Lasso di tempo: Baseline and 12 Months
Sexual avoidance will be assessed using a 4-item sexual avoidance questionnaire. This measure asks respondents to indicate how often they have avoided partnered and unpartnered sexual activity, respectively, on a scale of 0 (Never) to 4 (Always or Almost Always). If a response other than 0 is provided, respondents will be asked to check all options that apply from a list of reasons why they have avoided that type of sexual activity.
Baseline and 12 Months
Sexual self-efficacy as measured by the Sexual Self-Efficacy Questionnaire
Lasso di tempo: Baseline and 12 Months
Sexual self-efficacy will be assessed using the 26-item Sexual Self-Efficacy Questionnaire. Participants indicate which activities they believe they can do and rate their confidence in being able to perform those activities on a 10 to 100 scale.
Baseline and 12 Months
Sexual satisfaction as measured by a Sexual Satisfaction Questionnaire
Lasso di tempo: Baseline and 12 Months
Sexual satisfaction will be assessed using the Sexual Satisfaction Questionnaire, a 4-item measure assessing respondents' agreement with 4 statements related to sexual satisfaction on a scale of 1 (Not at all) to 7 (Extremely). Higher scores indicate higher sexual satisfaction.
Baseline and 12 Months
Sexual dysfunction as measured by a Sexual Dysfunction Questionnaire
Lasso di tempo: Baseline and 12 Months
Sexual dysfunction will be assessed using a Sexual Dysfunction Questionnaire, a 4-item measure assessing respondents' agreement with 4 statements related to sexual dysfunction on a scale of 1 (Extremely) to 6 (None or Never). Higher scores indicate higher sexual dysfunction.
Baseline and 12 Months
Sexual health information and support needs
Lasso di tempo: Baseline and 12 Months
A study-spcific Sexual Health Information and Support Needs questionnaire will be used to assess the importance of educational and supportive programming topics related to sexual health after prostate cancer treatment. Respondents will be asked to rate the importance of 12 related topics on a scale of 1 (Unimportant) to 5 (Very important). Respondents will also have the option to self-specify 'other' topics and rate the importance of those topics.
Baseline and 12 Months
Patient perceptions and opinions about guidelines
Lasso di tempo: Baseline and 12 Months
Patient perceptions and opinions about guidelines will be assessed using 3 study-specific guideline perception items included in the questionnaire set.
Baseline and 12 Months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Acceptability of Intervention Measure (AIM)
Lasso di tempo: 12 Months
The Acceptability of Intervention Measure will be completed by interventionists, providers, and research staff based on their experience delivering or supporting the study. Four items are rated on a 5-point agreement scale from "Completely disagree" to "Completely agree."
12 Months
Intervention Appropriateness Measure (IAM)
Lasso di tempo: 12 Months
The Intervention Appropriateness Measure will be completed by interventionists, providers, and research staff based on their experience delivering or supporting the study. Four items are rated on a 5-point agreement scale from "Completely disagree" to "Completely agree."
12 Months
Feasibility of Intervention Measure (FIM)
Lasso di tempo: 12 Months
The Feasibility of Intervention Measure will be completed by interventionists, providers, and research staff based on their experience delivering or supporting the study. Four items are rated on a 5-point agreement scale from "Completely disagree" to "Completely agree."
12 Months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Duke University

Investigatori

  • Investigatore principale: Rebecca A Shelby, PhD, Duke University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 luglio 2026

Completamento primario (Stimato)

1 luglio 2028

Completamento dello studio (Stimato)

1 luglio 2028

Date di iscrizione allo studio

Primo inviato

12 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

30 giugno 2026

Primo Inserito (Effettivo)

6 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • Pro00119667

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Sex Therapy

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Egypt

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi